TrueMark Investments LLC Buys 124,265 Shares of Novo Nordisk A/S $NVO

TrueMark Investments LLC grew its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 343.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 160,416 shares of the company’s stock after purchasing an additional 124,265 shares during the period. Novo Nordisk A/S makes up 1.5% of TrueMark Investments LLC’s investment portfolio, making the stock its 13th largest holding. TrueMark Investments LLC’s holdings in Novo Nordisk A/S were worth $8,901,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. JLB & Associates Inc. lifted its holdings in Novo Nordisk A/S by 0.7% in the third quarter. JLB & Associates Inc. now owns 219,624 shares of the company’s stock worth $12,187,000 after buying an additional 1,426 shares during the period. Vantage Investment Partners LLC raised its position in shares of Novo Nordisk A/S by 17.5% in the 3rd quarter. Vantage Investment Partners LLC now owns 533,565 shares of the company’s stock worth $29,608,000 after acquiring an additional 79,441 shares in the last quarter. Northstar Asset Management Inc. lifted its stake in shares of Novo Nordisk A/S by 31.1% in the 3rd quarter. Northstar Asset Management Inc. now owns 222,348 shares of the company’s stock valued at $12,338,000 after purchasing an additional 52,791 shares during the period. AAFMAA Wealth Management & Trust LLC boosted its position in shares of Novo Nordisk A/S by 1.3% during the third quarter. AAFMAA Wealth Management & Trust LLC now owns 15,130 shares of the company’s stock valued at $840,000 after purchasing an additional 201 shares in the last quarter. Finally, Parkside Financial Bank & Trust grew its stake in Novo Nordisk A/S by 18.8% in the third quarter. Parkside Financial Bank & Trust now owns 3,405 shares of the company’s stock worth $189,000 after purchasing an additional 538 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 0.0%

NYSE:NVO opened at $62.22 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.57 and a current ratio of 0.78. The firm has a market cap of $277.80 billion, a P/E ratio of 18.09 and a beta of 0.66. Novo Nordisk A/S has a fifty-two week low of $43.08 and a fifty-two week high of $93.80. The firm has a 50-day simple moving average of $52.13 and a two-hundred day simple moving average of $54.80.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. The firm had revenue of $11.79 billion for the quarter, compared to the consensus estimate of $11.98 billion. Analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

NVO has been the subject of several recent research reports. Morgan Stanley reissued an “underweight” rating and set a $42.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, December 3rd. Weiss Ratings reiterated a “sell (d+)” rating on shares of Novo Nordisk A/S in a research note on Monday, December 29th. HSBC reissued a “hold” rating and set a $54.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, December 10th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Novo Nordisk A/S in a research note on Wednesday, January 14th. Finally, The Goldman Sachs Group reiterated a “buy” rating on shares of Novo Nordisk A/S in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, eleven have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Hold” and an average price target of $56.21.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.